Novo's Ozempic Soars As Focus Shifts To Oral Semaglutide
Executive Summary
Sales of injectable semaglutide shored up Novo's second quarter, but all eyes are on the expected launch of an oral version in the third quarter.
You may also be interested in...
Novo Nordisk's Oral Rybelsus Priced On Par With Injectable GLP-1s, But Big Discounts May Be Needed
A 30-day supply of the first oral GLP-1 agonist will cost $772.43 in the US, similar to the injectable version but steeper than oral diabetes medicines. Deep discounts may be needed to secure market access.
US FDA Approval Of Novo Nordisk's Victoza For Young T2D Patients A Treatment Milestone
The new indication means Victoza is the first non-insulin drug approved to treat type 2 diabetes in young patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.
Gilead Increasingly Seems Focused On Combo Therapy In NASH
At EASL, Gilead indicated it may not take any of its current NASH candidates forward as monotherapy options. Trial collaboration with Novo Nordisk may suggest pessimism toward selonsertib after Phase III disappointment.